he’s also fighting to ... lower the cost of prescription drugs like insulin
Warnock will fight to lower prescription drug costs for families, including insulin costs.
Occurrences
Evidence
Reverend Warnock is fighting to lower the cost of prescription drugs for hardworking families, including lowering the cost of prescription drugs like insulin.
Sponsor: Sen. Warnock, Raphael G. [D-GA] (Introduced 02/11/2025). The bill is titled the Capping Prescription Costs Act of 2025 and seeks to limit cost-sharing for prescription drugs.
The legislation would cap annual out-of-pocket prescription drug costs per year at $2,000 for individuals and $4,000 for families with private insurance.
Section 11406 creates appropriate cost-sharing for covered insulin products under Medicare Part D, including no deductible and cost-sharing not to exceed the applicable copayment amount for a month’s supply.
Vote Result: Passed. Question: On Passage of the Bill: H.R. 5376, As Amended. This was the Senate’s final passage vote on the Inflation Reduction Act package that carried the insulin and prescription-drug provisions.
The law provides a yearly cap ($2,000 in 2025) on out-of-pocket prescription drug costs in Medicare and says people with Medicare who take insulin covered by their prescription drug plan will have access to each insulin for no more than $35 for a month’s supply.
Assessments
Warnock promised to fight to lower prescription drug costs, including insulin. During his Senate term, the Inflation Reduction Act passed with his chamber support and enacted major prescription-drug reforms, including a $35 monthly insulin cap for Medicare beneficiaries and a $2,000 annual Medicare out-of-pocket prescription-drug cap beginning in 2025. The delivery was not universal for all families or all private insurance insulin users, but the pledge was framed as fighting to lower costs rather than guaranteeing a comprehensive universal cap, and a substantial federal prescription-drug and insulin-cost reduction became law in the same term. His later sponsorship of broader prescription-cost cap legislation reinforces continued effort but is not needed for the core delivery finding.